Market revenue in 2023 | USD 227.6 million |
Market revenue in 2030 | USD 339.5 million |
Growth rate | 5.9% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 47.14% in 2023. Horizon Databook has segmented the Italy neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Italy contributed to around 10.0% of the global neurology clinical trials market in 2020. Clinical trials are frequently funded in Italy by pharmaceutical companies, they act as sponsors for trial. Italy is working for many years to become a major player in clinical studies owing to its top-level research institutions & hospitals present in the country.
As per Farmindustria, around 20% of the clinical trials in Europe are run in Italy. Italy also ranks first in terms of the number of value-based, Management Entry Agreements (MEAs) signed with pharmaceutical companies. Italy invested USD 3.3 billion in R&D in 2018. Such factors are expected to have a positive impact on neurology clinical trials market in Italy A significant number of aged people in the country suffer from dementia.
According to Dementia in Europe Yearbook 2019, over 1.3 million people in the country were estimated to have dementia. The high incidence of dementia in the country is expected to improve the demand for dementia clinical trials in the country. A large number of key players involved in conducting neurological clinical trials are present in Italy, including Medpace, Charles River, Covance, Icon, IQVIA, and Syneos Health. This is likely to have a positive impact on Italy neurology clinical trials market.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Italy neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account